Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that pediatric HSCT recipients, especially those with chronic graft-versus-host disease, are at risk for developing various nonmalignant late cutaneous changes such as vitiligo, psoriasis, alopecia, and nail changes.

In this review, the researchers found no statistically significant difference in overall survival and disease-free survival between busulfan/cyclophosphamide and total bone irradiation conditioning regimens for acute myeloid leukemia patients.

In this study, permanent alopecia after haematopoietic stem cell transplantation was found in 16% of patients and was significantly associated with conditioning regimens involving busulphan.

This study describes permanent scalp alopecia in patients receiving chemotherapy, radiation, or both, and highlights the need for further research to identify causative factors and mitigation strategies.

Patients often experience long-lasting changes to their hair after stem cell transplants.

This study identified two distinct histological patterns in permanent alopecia following bone marrow transplantation, suggesting links to myeloablative chemotherapy and chronic graft-versus-host disease.

This case report describes a 22-year-old woman who developed persistent, non-scarring hair loss and premature ovarian failure following a myeloablative umbilical cord transplant for acute myeloid leukemia.

In this study, researchers found that alkylating chemotherapy causes hair follicle stem cells to lose their regenerative ability by initially triggering proliferation followed by apoptosis, leading to permanent regeneration loss.

This study found that age is the most significant risk factor for hemorrhagic cystitis after hematopoietic stem-cell transplantation, with additional risk factors including cyclophosphamide-based prophylaxis and, among male recipients, prostatic hyperplasia.

In this review, researchers summarize drugs associated with scarring or permanent hair loss, notably after chemotherapy and tyrosine kinase inhibitor treatments, emphasizing the need for stronger evidence and long-term follow-up studies, as current findings are mostly from case reports.

This study found that in patients undergoing allogeneic hematopoietic stem-cell transplantation, older age significantly increases the risk of hemorrhagic cystitis, especially in males, who are also affected by prostatic hyperplasia.

Permanent hair loss after a stem cell transplant can be a sign of chronic immune system attack on the scalp.

This review discusses major dermatologic conditions occurring in the early post-hematopoietic stem cell transplant period and reports no new clinical results; it underscores dermatologists' role in recognizing critical complications.

This article discusses a unique case of permanent chemotherapy-induced alopecia in a patient receiving chemotherapy for breast cancer, characterized by a distinctive histologic finding and excludes bone marrow transplantation, but reports no new clinical results.

This case study reported a 23-year-old woman with chronic myeloid leukemia who developed permanent hair loss after chemotherapy and did not respond to topical minoxidil treatment.

This study found that permanent alopecia can occur after certain chemotherapy treatments and presents as nonscarring hair loss similar to androgenetic alopecia, with specific histological features that could be misdiagnosed without proper clinicopathological correlation.

This study observed that pediatric bone marrow transplantation patients frequently experience various dermatological issues; mucositis and xeroderma were the most common.

In this case study, donor lymphocyte infusions effectively eradicated measurable residual disease in a patient with relapsed acute myeloid leukemia after hematopoietic cell transplantation, while side effects included the development of vitiligo and alopecia areata, likely due to chronic graft-versus-host disease.

This article reviews adverse skin reactions caused by chemotherapy and cytokine treatments, describing specific and nonspecific reactions, but reports no new clinical findings.

This study reports that permanent and severe alopecia is a newly identified complication of the FEC 100–docetaxel regimen used for adjuvant breast cancer treatment.

This review discusses treatments for chemotherapy-induced alopecia, highlighting scalp cooling for hair loss prevention and 2% topical minoxidil for regrowth acceleration as effective options, but reports a need for more rigorous trials to validate promising new therapies.

In this case report, estrogen substitution therapy slightly increased hair volume in a 22-year-old patient with genetic predisposition to hair loss and alopecia caused by past treatment for leukemia, but hair loss returned after stopping the therapy.

This article reviews therapy-related hair disorders in oncology patients, detailing underlying mechanisms and potential management strategies, but reports no new clinical findings.

This review highlights that in children, hair loss can be attributed to diverse conditions like alopecia areata and tinea capitis, and stresses the importance of a holistic approach to diagnosis and management, including psychosocial support due to limited effective treatments.

This study found that adjuvant docetaxel treatment for breast cancer at cumulative doses of 400 mg/m² or higher is associated with a 10% prevalence of persistent alopecia leading to wig use, but this was completely prevented with scalp cooling.

This chapter details the causes and diagnostic process of pediatric alopecia, including trichoscopic findings, but reports no new clinical results.

This review elaborates on the skin side effects of chemotherapy and emphasizes identifying and managing both common and life-threatening skin reactions, without presenting new clinical findings.

This review outlines the advancements in organ and tissue transplantation since the discovery of the human MHC and reports no new clinical results.

This review discusses current knowledge and management strategies for chemotherapy-induced alopecia, highlighting the need for better research prioritization and providing patient support materials, but reports no new clinical results.

This article reviews drug-induced hair changes, highlighting that while many drugs are occasionally linked to hair loss, this connection has been conclusively established for only a few, and such hair loss is typically reversible.